Genetic Therapies

Praxis Secures $525M to Boost CNS Drug Development

BOSTON, October 16, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, has announced the successful pricing...

By cGxPwire Editor
October 17, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Genetic Therapies

Praxis Secures $525M to Boost CNS Drug Development